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Abstract
In case-control genetic association studies, cases are subjects with the disease and controls are subjects without the disease.
At the time of case-control data collection, information about secondary phenotypes is also collected. In addition to studies
of primary diseases, there has been some interest in studying genetic variants associated with secondary phenotypes. In
genetic association studies, the deviation from Hardy-Weinberg proportion (HWP) of each genetic marker is assessed as an
initial quality check to identify questionable genotypes. Generally, HWP tests are performed based on the controls for the
primary disease or secondary phenotype. However, when the disease or phenotype of interest is common, the controls do
not represent the general population. Therefore, using only controls for testing HWP can result in a highly inflated type I
error rate for the disease- and/or phenotype-associated variants. Recently, two approaches, the likelihood ratio test (LRT)
approach and the mixture HWP (mHWP) exact test were proposed for testing HWP in samples from case-control studies.
Here, we show that these two approaches result in inflated type I error rates and could lead to the removal from further
analysis of potential causal genetic variants associated with the primary disease and/or secondary phenotype when the
study of primary disease is frequency-matched on the secondary phenotype. Therefore, we proposed alternative
approaches, which extend the LRT and mHWP approaches, for assessing HWP that account for frequency matching. The
goal was to maintain more (possible causative) single-nucleotide polymorphisms in the sample for further analysis. Our
simulation results showed that both extended approaches could control type I error probabilities. We also applied the
proposed approaches to test HWP for SNPs from a genome-wide association study of lung cancer that was frequency-
matched on smoking status and found that the proposed approaches can keep more genetic variants for association
studies.
Citation: Wang J, Shete S (2011) Testing Hardy-Weinberg Proportions in a Frequency-Matched Case-Control Genetic Association Study. PLoS ONE 6(11): e27642.
doi:10.1371/journal.pone.0027642
Editor: Murielle Bochud, University Institute of Social and Preventive Medicine, Switzerland
Received May 26, 2011; Accepted October 21, 2011; Published November 14, 2011
Copyright:  2011 Wang, Shete. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health grant 1R01CA131324 and by a faculty fellowship from The University of Texas MD Anderson
Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment. This study makes use of lung cancer data obtained through NIH grants
R01CA55769, U19CA148127, and R01CA121197. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sshete@mdanderson.org
Introduction
Case-control genetic association studies using unrelated indi-
viduals to find genetic variations associated with a particular
disease are popular and useful. In a case-control study design,
cases are those subjects with the primary disease (e.g., lung cancer,
diabetes, breast cancer) and controls are those free of the primary
disease. In addition to the cases and controls with respect to the
primary disease, at the time of case-control collection, information
about secondary phenotypes, which we define as traits associated
with the primary disease of interest (i.e., predictors of the primary
disease), such as smoking behavior and body mass index (BMI), are
also collected. In addition to studies of primary diseases, there has
been some interest in studying genetic variants associated with
secondary phenotypes. Many case-control studies of primary
diseases are frequency-matched on the secondary phenotypes.
Frequency-matching on known risk confounders is an important
and commonly used study design in case-control studies [1] to
reduce the effects of confounding factors. For example, some lung
cancer studies are frequency-matched on smoking behavior, as
smoking is a known risk confounder for the association between
lung cancer and other risk factors.
In genetic association studies, the deviation from Hardy-
Weinberg proportion (HWP) of each genetic marker is typically
assessed as an initial quality check procedure to identify single-
nucleotide polymorphisms (SNPs) with questionable genotypes.
The genetic markers that deviate from HWP are usually
considered to be genotyping errors and are removed from further
analysis. In general, the HWP test assumes the genotypes are
sampled from the general population, and therefore, the expected
genotype counts in the test should be evaluated from the general
population. When the HWP test is conducted in only controls, the
observed control counts are compared against the expected
control counts. Recent papers [2–4] have shown, however, that
when the disease in a case-control study is common in the general
population, the controls (all of which do not have the disease) do
not accurately represent the general population. Therefore, using
only controls (of primary disease or secondary phenotype) for
HWP testing can result in highly inflated type I error probabilities
for the primary disease- and/or secondary phenotype-associated
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of the disease or secondary phenotype of interest.
Recently, new approaches have been proposed for assessing
HWP in the general population for genetic case-control associa-
tion studies [2–4]. The approaches proposed by Li and Li [2] and
Yu et al [4] are based on a general likelihood ratio framework.
The likelihood-based approach compares the likelihood that is
maximized under the alternative hypothesis with the likelihood
that is maximized under the null hypothesis (under HWP). Wang
and Shete [3] proposed a mixture HWP (mHWP) exact test that
uses a mixed sample of cases and controls that mimics the general
population. Both the likelihood-based approach and the mHWP
exact test can control the type I error rates for genetic variants
associated or unassociated with the primary disease.
Both the likelihood-based and mHWP approaches will work if
the study of primary disease is not frequency-matched (as shown in
the Supporting Information Table S1, Table S2, Table S3 and
Table S4). In this situation, individuals with the secondary
phenotype are randomly sampled from among the primary
disease cases and controls. However, if the case-control study is
frequency-matched on the secondary phenotype, individuals with
and without the secondary phenotype are not sampled randomly
but on the basis of the constraints of the primary disease cases and
controls. In this situation, both the likelihood-based approach and
the mHWP exact test would lead to the rejection of potential
causal variants associated with the primary disease and/or
secondary phenotype, which would decrease the likelihood of
identifying the causal or associated genetic variants in the follow-
up association studies. For example, for the mHWP exact test,
although the proportion of the primary disease in the mixture
sample would be similar to its prevalence in the general
population, the proportion of the presence of the secondary
phenotype may not be consistent with the prevalence of the
secondary phenotype in the general population, owing to the
frequency-matching design. Thus, using the recently proposed
approaches to assess HWP in the general population could
introduce artificial deviations from HWP and produce inflated
type I error rates for primary disease- and/or secondary
phenotype-associated genetic markers.
In this article, we show that when a case-control study of
primary disease was frequency-matched on the secondary
phenotype, all the existing approaches failed to conserve the type
I error probabilities. Therefore, we proposed alternative ap-
proaches for assessing HWP that account for frequency matching.
These approaches extend the likelihood ratio test (LRT) approach
[2] and the mHWP exact test [3]. We considered multiple
associated and unassociated genetic variants in frequency-matched
case-control studies with respect to the secondary phenotype.
Simulation studies performed to investigate the performance of the
proposed approaches showed that the type I error probabilities
were well controlled by both extended approaches. Furthermore,
we observed that, between the two approaches, the extended
mHWP exact test was more likely to keep potential secondary trait
and/or primary disease causal SNPs for further analysis when the
secondary phenotype was more common. We also applied the
proposed approaches to a real lung cancer case-control genetic
association study frequency-matched on smoking behavior.
Materials and Methods
We assumed a diallelic locus with two alleles, A and a.W e
denoted the three genotypes—AA, Aa, and aa—as a categorical
random variable, X=(0, 1, 2). If the allele frequency of A is p and
the allele frequency of a is (1-p), then the expected genotype
frequencies of AA, Aa, and aa are P0=p
2, P1=2p(1-p), and P2=
(1-p)
2, respectively, assuming HWP in the population. We defined
a binary random variable, D= (0, 1), to indicate the case-control
status of the primary disease, with 0 representing controls and 1
representing cases. We also defined the status of the secondary
phenotype as a binary random variable, T= (0, 1), with 0
representing absence of the secondary phenotype and 1 repre-
senting presence of the secondary phenotype. Let Kij denote the
joint probability of secondary phenotype T=i and primary disease
D=j, where i, j=0, 1, in the general population. The prevalence
of the primary disease in the general population is denoted as fD.I t
is easy to see that fD=K01 + K11. In our studies, we assumed that
the prevalence value and the joint probabilities Kij were known
because usually this information can be obtained from the
literature or previous studies. We assumed a case-control
association study of N individuals, with m controls and n cases,
with respect to the primary disease.
Extended likelihood ratio test (eLRT) approach
To extend the LRT approach, we followed a strategy similar to
that described by Li and Li [2]. To account for both primary
disease and secondary trait associations, we considered the
conditional probabilities of the genotypes given different primary
disease and secondary phenotype status for the likelihood-
based approach. We denoted this conditional probability as
Pr(X~kjT~i,D~j)=pijjkPk
 
Kij, where i, j=0, 1, k= 0 ,1 ,2 ,
and pijjk~Pr(T~i,D~jjX~k) is the conditional probability that
an individual is observed to have primary disease D=j and
secondary phenotype T=i given the genotype X=k. Given m
controls and n cases, we denoted mki as the number of individuals
in the control subjects with genotype X=k and secondary
phenotype T=i, and we denoted nki as the number of individuals
in the case subjects with genotype X=k and secondary phenotype
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The data are sampled from four trinomial distributions for the
genotypes, with each distribution corresponding to one of the
blocks of individuals with different primary disease and secondary
phenotype status; therefore, 8 parameters at most can be
estimated. The above likelihood function involves 15 parameters;
therefore, it is necessary to add multiple constraints to the
parameters. Let pjjk~Pr(D~jjX~k), j=0 ,1 ,a n dk=0, 1, and 2
denote the conditional probabilities of an individual with pri-




pijjk. Also, we know that p1jkzp0jk~1 for all k=0, 1,
and 2. We defined the genotype relative risk for genotype k
compared with reference genotype 0 for different scenarios:
rijk=pij|k/pij|0 and rjk=pj|k/pj|0 for k=1, 2 and both rij0 and rj0
equal to 1. Because we assumed that the joint probability of
primary disease and secondary phenotype Kij were known in
advance, the conditional probability pij|k can be expressed using
the joint probability and genotype relative risk as pij|k=Kijrijk/
(P0+rij1P1+rij2P2), with i, j=0, 1 and k=0, 1, and 2. Similarly,
because we fixed the prevalence of the primary disease, the
conditional probability pj|k can be expressed as pj|k=fDrjk/
(P0+rj1P1+rj2P2), with j=0, 1 and k=0, 1, and 2. The final
constraint was added for the genotype frequencies, where
.
Testing HWP for a Frequency-Matched Study
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27642P0+P1+P2=1. Given these constraints for the parameters, the

















   nk1 p1jk{p11jk
   nk0
p10jk
   mk1 1{p1jk{p10jk












for k=0, 1, and 2. We denoted
^ K Kij, ^ f fD, and ^ f fT as the estimated joint probability of secondary
phenotype and primary disease and the estimated prevalence
values of the primary disease and secondary phenotype in the
general population, respectively.
This modified likelihood function for hypothesis testing now
involves 8 parameters P1, P2, r111, r112, r101, r102, r11, r12 fg . Un-
der the null hypothesis that the genetic variant is in HWP,
P1=2p(1-p) and P2= (1-p)
2, with p as the minor allele frequency
(MAF). Thus, the number of parameters needing to be estimated
in the likelihood function is 7 under the null hypothesis and 8
under the alternative hypothesis that the genetic variant is not in
HWP. Therefore, the eLRT can be performed in a manner similar
to the test proposed by Li and Li [2]. The eLRT statistic is defined
as 2(ln(^ L L1){ln(^ L L0)), where ^ L L1 is the maximized likelihood
under the alternative hypothesis and ^ L L0 is the maximized
likelihood under the null hypothesis. Asymptotically, the test
statistic follows a one-degree-of-freedom chi-square distribution
under the null hypothesis. To maximize the likelihood, we
employed the ‘fminsearchcon’ function [5] in Matlab, which
implements the simplex algorithm.
Extended mHWP (emHWP) exact test
The basic concept of the extended mHWP (emHWP) is that,
given the data of a case-control association study of primary
disease frequency-matched on secondary phenotype, we try to
construct a mixture sample from the data to represent the general
population. In this mixture sample, the proportions of primary
disease and secondary phenotype can mimic the prevalence values
of primary disease and secondary phenotype in the general
population, respectively.
Consider a case-control study with N individuals, N=N00 + N10
+ N01 + N11, where Nij is the number of individuals in a block of
sample data with secondary trait status i and primary disease status
j, where i, j=0 ,1 .L e tNm be the sample size of the mixture sample.
To mimic the general population, the proportion of individuals in
the mixture sample with secondary trait status i and primary
disease status j should be consistent with the corresponding joint
probability in the general population. Therefore, in the mixture
sample, the number of individuals with secondary phenotype i and
primary disease j should be Nm|^ K Kij (Figure S1). Foreachblock of
individuals with secondary phenotype i and primary disease j, the
number of individuals in the mixture sample must be less than the
number in the original dataset. So, Nm|^ K Kij # Nij, and Nm #
min(N00=^ K K00,N01=^ K K01,N10=^ K K10,N11=^ K K11). In our study, we chose
Nm=min(N00=^ K K00,N01=^ K K01,N10=^ K K10,N11=^ K K11) to achieve the larg-
est possible mixture sample size and then randomly sampled
Nm|^ K Kij individuals from the blocks of individuals with secondary
phenotype i and primary disease j. In the mixture sample, the HWP
exact p value was evaluated [6]. We then employed the re-sampling
procedure to obtain M mixture samples and assess M HWP exact p
values, as was done in the original study by Wang and Shete [3].
The empirical distribution-based non-parametric density was
constructed on the basis of M mixture sample p values (please see
details of kernel density estimation in [3]). The maximum likelihood
estimator (MLE) of this empirical distribution was obtained as the
final estimate of p value for the emHWP exact test in the general
population. Simulations were conducted to decide the number of
mixture samples M, and we selected M=500 in our study.
Simulation studies
We performed simulation studies to investigate the performance
of the proposed eLRT and emHWP approaches, and compared
the proposed approaches to the existing approaches for HWP
testing: the LRT approach proposed by Li and Li [2] and the
mHWP exact test proposed by Wang and Shete [3]. We
considered four independent SNPs with different associations to
the primary disease and/or secondary phenotype. In addition to
the genetic risk factors, we also accounted for environmental
factors, including sex, ethnicity, and age, in the simulation models.






In the two logistic models, Xi, i=1, …, 4, represent random
variables of SNPs, and Xsex, Xethn, and Xage represent random
variables corresponding to the environmental factors. The first
logistic model was used to generate secondary phenotype status
given the dataset of realizations of SNPs and environmental
factors. Then, the primary disease status was generated using the
second logistic model, which was conditional on the values of
SNPs, environmental factors, and the secondary phenotype. We
defined all the regression coefficients (ai, i=1, …, 7 and bi, i=1,
…, 8) and prevalences of the genetic and environmental factors
for the purpose of the simulation studies, as listed in Table 1. With
these settings, we assumed different associations of generic
variants: (1) SNP1 is associated with both primary disease and
secondary phenotype; (2) SNP2 is associated with primary disease
only; (3) SNP3 is associated with secondary phenotype only; and (4)
SNP4 is not associated with either primary disease or secondary
phenotype. The associations among all the generic variants,
environmental factors, secondary phenotype, and primary disease
can be represented by a network structure, as shown in Figure S2
in the Supporting Information.
The genotypes of the SNPs were generated with the use of the
genotype frequencies assuming the SNPs were in HWP. In the
simulation study, we assumed that the SNPs were common SNPs
with an MAF of 40% or less common SNPs with an MAF of 10%.
The values of the environmental factors were generated on the
basis of their prevalence values. By using different values for the
intercept coefficients a0 and b0, we defined different prevalence
values for the primary disease and secondary phenotype in the
general population, ranging from 10% to 70%, which can
represent different common diseases and common secondary
traits. We did not study the scenario of a very rare disease or
secondary phenotype (e.g., prevalence , 5%) because it has been
shown in the previous studies [2,3] that the standard approach for
testing HWP based on controls only (with respect to the primary
disease or secondary phenotype) can work well in those situations.
Given the values of the genetic variants and environmental
factors, for each scenario (i.e., one pair of specific fD and fT), we
,
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based on the above logistic models. Therefore, the joint probability
of primary disease and secondary phenotype, ^ K Kij, i, j=0, 1, can be
estimated from the simulated population, which would be used
later in the analysis based on the proposed approaches. The case-
control status was simulated assuming a dominant genetic model
for all genetic variants; however, the proposed approaches are not
restricted to a dominant genetic model. When a frequency-
matched study based on the secondary trait is considered, the
proportions of individuals with the secondary phenotype should be
approximately equal in primary disease cases and controls [1].
That is, given that the secondary trait T is a binary random
variable, the frequency-matching case-control design can be
expressed using the following inequality based on conditional
probabilities: | Pr(T=1|D=0)-Pr(T=1|D=1)|# c, where c
is a small fraction. We assumed the constant c=0.02 in our study.
Therefore, we first randomly sampled the cases of primary disease
and estimated the proportion of individuals with the secondary
phenotype, Pr(T=1|D=1). According to the estimated Pr(T=1
| D=1), the proportion of individuals with the secondary
phenotype in primary disease controls, Pr(T=1 | D=0), was
assessed as a random number from a uniform distribution
(Pr(T=1 | D=1) – c, Pr(T=1 | D=1) + c). The controls were
then sampled to satisfy this estimated proportion, Pr(T=1|D=0).
In this way, we simulated 1,000,000 replicates, each with 2,000




We report the observed type I error probabilities of the different
approaches for testing HWP at two different significance levels for
all the scenarios (i.e., the different combinations of prevalence
values for the primary disease and secondary phenotype). In
addition to the 0.05 nominal significance level used for candidate
gene association studies, we considered the nominal significant
level 0.0001, which is used as a threshold for HWP testing in
genome-wide association studies [7]. All the results were evaluated
based on 1,000,000 replicates. For the common SNPs (MAF
=40%), the results associated with SNP1, SNP2, SNP3, and SNP4
are reported in Tables 2, 3, 4, 5, respectively. For the less common
SNPs (MAF=10%), the results are reported in Tables 6, 7, 8, 9,
respectively. Four existing approaches for testing HWP and the
two proposed approaches were studied: LRT_t and mHWP_t are
the LRT approach [2] and the mHWP exact test [3], respectively,
which use the presence and absence of the secondary phenotype as
cases and controls; LRT_d and mHWP_d use the presence and
absence of the primary disease as cases and controls; the eLRT
approach proposed in this article is an extension of the LRT
approach proposed by Li and Li [2]; and the emHWP exact test
proposed in this article is an extension of the mHWP exact test
proposed by Wang and Shete [3].
Table 2 reports the type I error probabilities of different
approaches for testing HWP for SNP1 (MAF=40%) at 0.05 and
0.0001 significance levels. SNP1 was associated with both the
primary disease and the secondary phenotype in the simulations.
The LRT approach and the mHWP exact test using individuals
with presence and absence of the secondary phenotype as cases
and controls (LRT_t and mHWP_t) provided similar type I error
rates, and neither could control the type I error rate in most of the
scenarios. Both approaches also performed very similarly when
using individuals with presence and absence of the primary disease
as cases and controls (LRT_d and mHWP_d); both could control
the type I error rate in more scenarios than LRT_t and mHWP_t
but still resulted in an inflated type I error rate in many scenarios.
Finally, the newly proposed eLRT approach and emHWP exact
test both controlled the type I error rate well. For example, when
prevalence values of both the primary disease and secondary
phenotype were 0.3, given a 0.05 significance level, the type I error
rates of the LRT_t, mHWP_t, LRT_d, and mHWP_d approaches
were 0.207040, 0.215840, 0.118910, and 0.125500, respectively,
which were all highly inflated; the type I error rates of the eLRT
and emHWP approaches were 0.050629 and 0.045782, respec-
tively, which agreed very well with the nominal significance value
of 0.05. When the nominal significance level was 0.0001 and both
fD and fT were set as 0.3, we observed a similar trend in type I
errors: the type I error rates of the existing approaches were
0.003054, 0.002029, 0.000867 and 0.000449, respectively, which
were highly inflated, whereas the type I error rates of the eLRT
and emHWP approaches were 0.000162 and 0.000019, respec-
tively, which agreed very well with the nominal significance value
of 0.0001.
When the genetic variant was only associated with the primary
disease (SNP2, Table 3), the LRT approach and the mHWP exact
Table 1. Parameters for simulation studies.
Coefficients of logistic models
Factors a coefficients b coefficients Prevalence
SNP1 a1=0.4055 (OR=1.5) b1=0.4055 (OR=1.5)
SNP2 a2=0(OR=1) b2=0.4055 (OR=1.5)
SNP3 a3=0.4055 (OR=1.5) b3=0 (OR=1)
SNP4 a4=0(OR=1) b4=0 (OR=1)
Sex a5=0.6931 (OR=2) b5=0 (OR=1) 50% (Male)
Ethnicity a6=0.4055 (OR=1.5) b6=0.4055 (OR=1.5) 75% (Caucasian)
Age
0-30 a7=0 (OR for additive model=1) b7=0.4055 (OR for additive model=1.5) 36%
31-50 39%
Secondary Trait NA b8=1.0983 (OR=3)
doi:10.1371/journal.pone.0027642.t001
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as cases and controls (LRT_d and mHWP_d) could conserve the
type I error rates for all the scenarios. This was expected because
SNP2 was associated with the primary disease only, and this
assumption was the focus in the original studies of these two
approaches [2,3]. However, LRT_t and mHWP_t led to inflated
type I error rates. And again, we observed that the type I error
rates were well controlled by both of the proposed approaches,
eLRT and the emHWP exact test.
When the genetic variant was only associated with the
secondary phenotype (SNP3, Table 4), it was not surprising to
see that the LRT approach and the mHWP exact test using
individuals with presence and absence of the secondary phenotype
as cases and controls (LRT_t and mHWP_t) could control the type
I error rates in all scenarios. However, LRT_d and mHWP_d led
to inflated type I error rates in many situations. As in the results for
SNP1 and SNP2, both the proposed approaches (eLRT and
emHWP) still controlled type I error rates well for all scenarios.
Last, when the genetic variant was not associated with the
primary disease or the secondary phenotype (SNP4, Table 5), all of
theapproachescontrolledthe typeIerrorrates wellforall scenarios.
Therefore, the results reported in Tables 2, 3, 4, 5 for the
common SNPs (MAF=40%) show that the proposed eLRT and
emHWP approaches could control the type I error rates for all
SNPs with different types of associations with primary or
secondary phenotypes and all scenarios with different prevalence
values. It also should be noted that when the primary disease was
less common (e.g., ^ f fD = 0.1 , 0.5) and the secondary phenotype
Table 2. Estimated type I error probability for test of deviation from HWP of SNP1, a causal SNP to both primary disease and
secondary phenotype (MAF=40%), at 0.05 and 0.0001 significance levels in simulation studies* using different approaches for
HWP testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.629540 0.575270 0.554130 0.562720 0.053358 0.041523 0.035780 0.038847
0.3 0.215320 0.207040 0.206470 0.201280 0.003199 0.003054 0.002981 0.002936
0.5 0.050372 0.048842 0.049259 0.049460 0.000067 0.000060 0.000111 0.000088
0.7 0.210240 0.206540 0.205710 0.205040 0.003146 0.002987 0.002762 0.002758
mHWP_t 0.1 0.633310 0.584310 0.536340 0.484760 0.052694 0.027412 0.010742 0.006781
0.3 0.216690 0.215840 0.205520 0.169840 0.003171 0.002029 0.000832 0.000479
0.5 0.050907 0.053288 0.052970 0.046346 0.000067 0.000056 0.000050 0.000016
0.7 0.212230 0.216690 0.220330 0.216660 0.003372 0.002963 0.002298 0.001488
LRT_d 0.1 0.082900 0.176400 0.179690 0.121400 0.000366 0.001921 0.002132 0.001113
0.3 0.062015 0.118910 0.137840 0.106030 0.000193 0.000867 0.001054 0.000592
0.5 0.056323 0.081140 0.096205 0.082865 0.000109 0.000253 0.000700 0.000413
0.7 0.050907 0.059385 0.064534 0.061732 0.000212 0.000144 0.000289 0.000109
mHWP_d 0.1 0.086345 0.181400 0.184410 0.125150 0.000306 0.001731 0.001913 0.000965
0.3 0.067275 0.125500 0.144800 0.112180 0.000058 0.000449 0.000555 0.000413
0.5 0.054004 0.077626 0.092293 0.079165 0.000099 0.000235 0.000621 0.000393
0.7 0.055775 0.064159 0.069567 0.066528 0.000116 0.000054 0.000153 0.000054
eLRT 0.1 0.050846 0.050180 0.049620 0.049718 0.000068 0.000059 0.000122 0.000038
0.3 0.048648 0.050629 0.049565 0.050288 0.000102 0.000162 0.000109 0.000130
0.5 0.049669 0.049533 0.049771 0.050028 0.000108 0.000089 0.000062 0.000078
0.7 0.049458 0.048902 0.050458 0.049812 0.000179 0.000074 0.000111 0.000061
emHWP 0.1 0.055737 0.049401 0.037640 0.022980 0.000040 0.000006 0.000012 0.000010
0.3 0.051877 0.045782 0.033138 0.020467 0.000014 0.000019 0.000021 ,0.000001
0.5 0.052006 0.053254 0.044670 0.029965 0.000082 0.000011 0.000008 ,0.000001
0.7 0.054092 0.053385 0.054638 0.054220 0.000138 0.000041 0.000107 0.000019
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t002
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tended to have a larger type I error rate than the emHWP exact
test, which means that the emHWP exact test is more likely to keep
the promising genetic variants than the eLRT approach in these
situations. It is possible that actual studies of primary disease and
secondary phenotype could fall within these ranges of prevalence
values. For example, in a study of overweight based on data
collected for studying type 2 diabetes, the prevalence of type 2
diabetes (primary disease) was about 10% in the U.S. [8] and the
prevalence of overweight was about 66% in the U.S. [9]. In this
situation, the emHWP test would be preferable to the eLRT
approach. At a very low nominal significance level (0.0001), the
eLRT, but not the emHWP, approach had a slightly inflated type
I error rate. Thus, the emHWP exact test is also more likely to
keep the promising genetic variants than the eLRT approach at a
low nominal significance level.
When the SNPs of interest were less common (MAF=10%,
Tables 6, 7, 8, 9), we observed similar trends in the results for all
SNPs with different associations. As expected, the inflation in type
I error rates of the existing approaches was not as significant as
that for common SNPs (MAF=40%, Tables 2, 3, 4, 5). Especially,
we noticed that the LRT_d and mHWP_d approaches could
conserve the type I error better in many, but not all, situations. For
example, for SNP1 (Table 6, associated with both the primary
disease and secondary phenotype), when the prevalence values of
both primary disease and secondary phenotype were 0.3, given a
0.05 significance level, the type I error rates of the different
existing approaches were 0.072453, 0.066110, 0.058761, and
Table 3. Estimated type I error probability for test of deviation from HWP of SNP2, a causal SNP to primary disease but
unassociated with secondary phenotype (MAF=40%), at 0.05 and 0.0001 significance levels in simulation studies* using different
approaches for HWP testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.627260 0.573700 0.550220 0.559390 0.053796 0.040312 0.034674 0.037743
0.3 0.210050 0.198150 0.200780 0.196990 0.003259 0.002515 0.002577 0.002789
0.5 0.050007 0.049852 0.049675 0.051325 0.000071 0.000113 0.000062 0.000160
0.7 0.216220 0.219080 0.217210 0.215410 0.003184 0.003390 0.003172 0.002850
mHWP_t 0.1 0.631460 0.584970 0.536990 0.488360 0.053770 0.026639 0.010651 0.007235
0.3 0.210800 0.208130 0.200800 0.168160 0.003330 0.001737 0.000933 0.000374
0.5 0.050602 0.054912 0.054477 0.048824 0.000073 0.000057 0.000016 0.000005
0.7 0.218030 0.229660 0.232740 0.228650 0.003316 0.003497 0.002618 0.001366
LRT_d 0.1 0.050558 0.050690 0.050830 0.051459 0.000092 0.000117 0.000148 0.000103
0.3 0.051329 0.055468 0.056119 0.052864 0.000089 0.000129 0.000150 0.000111
0.5 0.050079 0.054422 0.055539 0.053985 0.000067 0.000120 0.000057 0.000145
0.7 0.050483 0.051177 0.051220 0.050447 0.000094 0.000136 0.000103 0.000107
mHWP_d 0.1 0.054121 0.054870 0.054884 0.055146 0.000067 0.000117 0.000097 0.000100
0.3 0.056680 0.061018 0.061881 0.057905 0.000077 0.000068 0.000089 0.000040
0.5 0.048408 0.052943 0.053900 0.052227 0.000067 0.000145 0.000057 0.000132
0.7 0.055468 0.056702 0.056614 0.056278 0.000024 0.000100 0.000055 0.000081
eLRT 0.1 0.050108 0.049843 0.049292 0.050494 0.000096 0.000125 0.000095 0.000046
0.3 0.050273 0.050039 0.049661 0.050889 0.000065 0.000133 0.000101 0.000102
0.5 0.049889 0.050504 0.049880 0.050395 0.000076 0.000065 0.000070 0.000105
0.7 0.049888 0.049224 0.051004 0.050025 0.000068 0.000139 0.000087 0.000115
emHWP 0.1 0.055240 0.050562 0.038818 0.025086 0.000070 0.000032 0.000012 0.000012
0.3 0.053956 0.046384 0.034750 0.022099 0.000047 0.000008 0.000012 0.000008
0.5 0.052390 0.055258 0.046097 0.032279 0.000076 0.000041 0.000020 ,0.000001
0.7 0.055004 0.054376 0.055794 0.054795 0.000002 0.000085 0.000046 0.000102
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t003
Testing HWP for a Frequency-Matched Study
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e276420.053680, respectively, whereas the type I error rates of the
proposed approaches were 0.049599 and 0.035411, respectively,
which were well-controlled at the 0.05 level. The performance of
the emHWP exact test for the less common SNPs was very similar
to that for the common SNPs at both the 0.05 and 0.0001
significance levels for all scenarios. However, the eLRT approach
had inflated type I error rates at the 0.0001 level of significance in
some situations for the less common SNPs. This observation
further suggested that the emHWP exact test is more favorable
than the eLRT approach in these situations.
Although the previously proposed LRT approach and mHWP
exact test would work for certain SNPs in some scenarios, in
reality, the HWP tests are performed before the association tests.
Therefore, one would not know the underlying real associations of
SNPs with the primary disease and/or secondary phenotype when
performing the HWP tests, and the existing approaches might lead
to the removal of genetic variants potentially associated with the
primary disease and/or secondary phenotype. In contrast, the
proposed emHWP test performed uniformly well at controlling the
type I error rates for all four SNPs with different associations to the
primary disease and secondary phenotype in all scenarios.
We also conducted simulation studies to evaluate the perfor-
mances of all the approaches to HWP testing for the unmatched
case-control study of primary disease and reported the type I error
results in Supporting Information Tables S1, S2, S3, S4. We
considered common SNPs with MAF=40% and defined different
prevalence values for primary disease and secondary phenotype in
the general population, ranging from 10% to 90%. The type I errors
Table 4. Estimated type I error probability for test of deviation from HWP of SNP3, a causal SNP to secondary phenotype but
unassociated with primary disease (MAF=40%), at 0.05 and 0.0001 significance levels in simulation studies* using different
approaches for HWP testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.050237 0.049513 0.050059 0.049689 0.000102 0.000110 0.000117 0.000056
0.3 0.049339 0.049678 0.049446 0.048962 0.000108 0.000116 0.000108 0.000139
0.5 0.049916 0.050404 0.049220 0.049619 0.000098 0.000158 0.000111 0.000080
0.7 0.049775 0.050679 0.049866 0.050453 0.000059 0.000130 0.000118 0.000171
mHWP_t 0.1 0.052723 0.053571 0.046324 0.032064 0.000102 0.000053 ,0.000001 ,0.000001
0.3 0.050644 0.054787 0.049998 0.038074 0.000108 0.000015 0.000037 ,0.000001
0.5 0.050812 0.055255 0.053091 0.045548 0.000122 0.000111 0.000042 0.000004
0.7 0.049322 0.053758 0.054543 0.053817 0.000059 0.000132 0.000078 0.000069
LRT_d 0.1 0.091228 0.203020 0.202380 0.132960 0.000471 0.002732 0.003004 0.001147
0.3 0.072172 0.158300 0.184610 0.131600 0.000233 0.001944 0.002358 0.001177
0.5 0.058820 0.103760 0.127970 0.109320 0.000192 0.000643 0.001143 0.000612
0.7 0.051530 0.063688 0.073503 0.071796 0.000130 0.000196 0.000318 0.000314
mHWP_d 0.1 0.093969 0.208080 0.207090 0.136520 0.000448 0.002430 0.002673 0.001069
0.3 0.077520 0.166330 0.193820 0.138970 0.000144 0.001229 0.001499 0.000816
0.5 0.056407 0.099694 0.123440 0.104840 0.000180 0.000568 0.001051 0.000553
0.7 0.056720 0.069087 0.078565 0.077589 0.000108 0.000100 0.000160 0.000221
eLRT 0.1 0.050286 0.049335 0.050350 0.049391 0.000137 0.000111 0.000196 0.000111
0.3 0.049295 0.049636 0.049703 0.048950 0.000097 0.000118 0.000107 0.000123
0.5 0.049719 0.049851 0.049578 0.049965 0.000152 0.000104 0.000117 0.000093
0.7 0.049215 0.049359 0.050344 0.050839 0.000178 0.000141 0.000057 0.000179
emHWP 0.1 0.054900 0.049287 0.038968 0.023448 0.000078 0.000036 0.000020 ,0.000001
0.3 0.052976 0.045988 0.033970 0.019914 0.000056 ,0.000001 0.000024 0.000003
0.5 0.052207 0.054182 0.045483 0.030691 0.000152 0.000060 0.000022 ,0.000001
0.7 0.053854 0.054086 0.055279 0.055419 0.000089 0.000065 0.000033 0.000095
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t004
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were based on 1,000 replicates, each with 1,000 primary disease
cases and 1,000 randomly sampled controls. As in the frequency-
matched case-control studies, the proposed eLRT approach and the
emHWP exacttest wereboth ableto control the type I errorratesfor
all SNPs and all scenarios in the unmatched case-control studies.
Therefore,theproposedeLRTapproachandemHWPexacttestare
robust for different study designs. In addition, the LRT approach
and the mHWP exact test using individuals with presence and
absence of primary disease as cases and controls also performed well
for all SNPs and all scenarios, as expected.
Application to lung cancer data
To examine the performance of the proposed eLRT and
emHWP approaches, we also applied them to the case-control
study of lung cancer frequency-matched on smoking status. This
analysis included 2,291 individuals, with 1,154 lung cancer
patients and 1,137 controls frequency-matched to the cases by
age, sex, and smoking status [10]. The data were collected for a
case-control study of lung cancer. All the case and control subjects
were ever smokers: 1,260 former smokers and 1,031 current
smokers. All the individuals were Caucasian. Lung cancer cases
were accrued at The University of Texas MD Anderson Cancer
Center and were histologically confirmed. Controls were ascer-
tained through a multi-specialty physician practice from the same
area. Questionnaire data were obtained by personal interview in
the original study. This study was approved by the institutional
review board at MD Anderson Cancer Center, and all participants
provided written informed consent (LAB10-0347). In the lung
cancer genome-wide association study, 317,498 tagging SNPs
Table 5. Estimated type I error probability for test of deviation from HWP of SNP4, a SNP unassociated with secondary phenotype
and primary disease (MAF=40%), at 0.05 and 0.0001 significance levels in simulation studies* using different approaches for HWP
testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.049895 0.051331 0.049151 0.049731 0.000081 0.000101 0.000142 0.000115
0.3 0.050845 0.050014 0.048887 0.050541 0.000056 0.000080 0.000100 0.000104
0.5 0.049367 0.048765 0.051168 0.049342 0.000081 0.000124 0.000131 0.000173
0.7 0.050228 0.049878 0.049212 0.050788 0.000049 0.000024 0.000086 0.000070
mHWP_t 0.1 0.052873 0.056271 0.046639 0.033368 0.000089 0.000064 0.000024 ,0.000001
0.3 0.052488 0.055169 0.050527 0.040863 0.000060 0.000067 0.000033 0.000035
0.5 0.050102 0.053512 0.055504 0.047180 0.000081 0.000106 0.000077 0.000014
0.7 0.049741 0.052617 0.054543 0.054514 0.000052 0.000022 0.000065 0.000039
LRT_d 0.1 0.051678 0.052132 0.050314 0.049756 0.000103 0.000075 0.000064 0.000098
0.3 0.050903 0.049942 0.048878 0.051188 0.000067 0.000130 0.000204 0.000140
0.5 0.049440 0.048856 0.050964 0.049971 0.000087 0.000101 0.000135 0.000160
0.7 0.050011 0.049740 0.050224 0.052106 0.000078 0.000043 0.000090 0.000070
mHWP_d 0.1 0.054502 0.055479 0.053625 0.053484 0.000093 0.000073 0.000052 0.000084
0.3 0.055727 0.055445 0.054290 0.056204 0.000029 0.000059 0.000101 0.000110
0.5 0.047628 0.047015 0.049317 0.047875 0.000062 0.000109 0.000135 0.000156
0.7 0.055520 0.055276 0.055206 0.057024 0.000052 0.000027 0.000032 0.000055
eLRT 0.1 0.051447 0.051662 0.050660 0.049422 0.000048 0.000111 0.000135 0.000088
0.3 0.050599 0.049412 0.048554 0.051584 0.000061 0.000074 0.000095 0.000073
0.5 0.049071 0.048852 0.050214 0.050171 0.000082 0.000111 0.000170 0.000114
0.7 0.049997 0.049947 0.049675 0.051680 0.000105 0.000076 0.000127 0.000121
emHWP 0.1 0.056339 0.052359 0.040427 0.025242 0.000017 0.000029 0.000013 0.000007
0.3 0.054430 0.046910 0.034919 0.022838 0.000014 0.000025 0.000014 ,0.000001
0.5 0.052086 0.053611 0.046387 0.031905 0.000082 0.000072 0.000036 0.000014
0.7 0.054686 0.055224 0.054902 0.056712 0.000065 0.000041 0.000034 0.000065
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t005
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this study. We further excluded the SNPs with MAF , 0.05, and
therefore, 300,738 SNPs were left in the analysis.
We were interested in determining how many SNPs would be
rejected in the quality check procedure using the different
approaches for testing HWP. From the simulation studies, we
found that the LRT approach and mHWP exact test performed
very similarly; therefore, we only reported the results obtained using
the LRT approach with either (1) the presence and absence of lung
cancer as cases and controls (LRT_d) or (2) current and former
smokers as cases and controls (LRT_t). To evaluate eLRT and
emHWP, we first obtained the prevalence values of lung cancer ^ f fD
andcurrent smokers ^ f fT ineversmokersfromtheliterature (0.14and
0.498, respectively) [12,13]. We then estimated the conditional
probability of lung cancer cases given current smokers in the ever
smokers as 0.2545 [12]. Therefore, we could calculate the estimated
joint probabilities of lung cancer and smoking status ^ K Kij, where i,
j=0, 1, with 1 representing lung cancer patients and current
smokers and 0 representing lung cancer-free controls and former
smokers. For example, ^ K K11 = 0.2545 6 0.14=0.0356 and
^ K K10 =0.14 – 0.0356=0.1044. ^ K K01 and ^ K K00 can then be calculated
accordingly. Table 10 reports the numbers of SNPs that would be
rejected and removed in the quality check procedure using the
different HWP testing approaches, including LRT_d, LRT_t,
eLRT, and emHWP, at different commonly used nominal
significance levels (from 0.005 to 0.000001) in genome-wide
association studies. We observed that for all significance levels, the
proposed eLRT and emHWP approaches always rejected fewer
Table 6. Estimated type I error probability for test of deviation from HWP of SNP1, a causal SNP to both primary disease and
secondary phenotype (MAF=10%), at 0.05 and 0.0001 significance levels in simulation studies* using different approaches for
HWP testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.162010 0.153420 0.150040 0.152840 0.001597 0.001321 0.001332 0.001540
0.3 0.078159 0.072453 0.071508 0.072241 0.000309 0.000347 0.000336 0.000353
0.5 0.051000 0.049919 0.050700 0.049936 0.000118 0.000068 0.000063 0.000080
0.7 0.071504 0.072624 0.070306 0.072665 0.000174 0.000309 0.000361 0.000241
mHWP_t 0.1 0.149180 0.135750 0.108590 0.078171 0.001100 0.000328 0.000048 0.000010
0.3 0.070424 0.066110 0.056082 0.040867 0.000250 0.000092 0.000010 0.000011
0.5 0.049444 0.051274 0.049291 0.040294 0.000123 0.000038 0.000022 0.000005
0.7 0.076373 0.082008 0.081561 0.081048 0.000240 0.000318 0.000295 0.000101
LRT_d 0.1 0.056718 0.068336 0.067064 0.058557 0.000248 0.000260 0.000204 0.000139
0.3 0.055615 0.058761 0.059443 0.056363 0.000104 0.000120 0.000239 0.000162
0.5 0.051958 0.054015 0.055546 0.052000 0.000128 0.000075 0.000121 0.000079
0.7 0.052333 0.052450 0.051962 0.053095 0.000102 0.000166 0.000200 0.000119
mHWP_d 0.1 0.053442 0.063423 0.062436 0.054951 0.000164 0.000132 0.000063 0.000096
0.3 0.052441 0.053680 0.053728 0.051717 0.000022 0.000047 0.000054 0.000050
0.5 0.045016 0.045112 0.046540 0.043593 0.000077 0.000032 0.000077 0.000079
0.7 0.051805 0.051895 0.050645 0.051822 0.000053 0.000086 0.000084 0.000052
eLRT 0.1 0.052115 0.052281 0.054407 0.075478 0.000311 0.000155 0.000511 0.001738
0.3 0.052444 0.049599 0.052305 0.059940 0.000113 0.000149 0.000202 0.000639
0.5 0.051163 0.049736 0.050396 0.056037 0.000155 0.000060 0.000073 0.000300
0.7 0.054020 0.052456 0.051402 0.058749 0.000111 0.000155 0.000187 0.000327
emHWP 0.1 0.049613 0.040647 0.027971 0.016156 0.000065 0.000012 0.000013 ,0.000001
0.3 0.048224 0.035411 0.024398 0.013660 0.000016 0.000002 ,0.000001 ,0.000001
0.5 0.050066 0.048976 0.038241 0.024400 0.000115 0.000024 ,0.000001 ,0.000001
0.7 0.052258 0.051763 0.049974 0.051433 0.000071 0.000102 0.000107 0.000059
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t006
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rejected the fewest SNPs, whereas LRT_t always rejected the most
SNPs, among all four approaches. For example, when the nominal
significance level was 0.0001, 1,121 and 812 SNPs would be
rejected andremovedbyusingtheLRT_tandLRT_d, respectively,
whereas only 798 and 637 SNPs would be rejected and removed by
using the proposed eLRT and emHWP approaches, respectively.
ComparedwiththeLRT_tapproach,theemHWPapproachwould
keep 484 more SNPs for further analysis of the association of lung
cancer and/or smoking status.
Discussion
In this article, we propose two new approaches (eLRT and
emHWP) for testing HWP in genetic association studies in which
the primary disease cases and controls are frequency-matched on
the secondary phenotype. These two approaches are extensions of
two recently proposed approaches, the LRT approach [2] and the
mHWP exact test [3], that further account for the frequency-
matching design with respect to the secondary phenotype. When
the case-control study of primary disease is frequency-matched
based on the secondary phenotype, which is correlated with the
primary disease, statistically speaking, it can be considered to
analyze one phenotype with four possible categories, and the
likelihood function in the eLRT approach was constructed under
this scenario. Similar thinking could be applied to the development
of the emHWP exact test. Moreover, the approaches proposed can
be extended to obtain estimates and standard errors of the allele
frequency. The performance of the two approaches was
investigated via simulation studies, as well as an analysis of an
Table 7. Estimated type I error probability for test of deviation from HWP of SNP2, a causal SNP to primary disease but
unassociated with secondary phenotype (MAF=10%), at 0.05 and 0.0001 significance levels in simulation studies* using different
approaches for HWP testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.161340 0.154220 0.148260 0.148780 0.001358 0.001472 0.001255 0.001499
0.3 0.076030 0.074891 0.074848 0.073556 0.000307 0.000159 0.000388 0.000311
0.5 0.051226 0.050695 0.049906 0.051283 0.000158 0.000184 0.000166 0.000090
0.7 0.069704 0.071344 0.067986 0.070402 0.000182 0.000189 0.000176 0.000303
mHWP_t 0.1 0.146860 0.141050 0.117140 0.085517 0.000991 0.000629 0.000140 0.000036
0.3 0.066561 0.068085 0.061517 0.045970 0.000224 0.000075 0.000052 0.000000
0.5 0.048454 0.051398 0.049869 0.044307 0.000104 0.000113 0.000036 0.000026
0.7 0.073637 0.079299 0.077750 0.078682 0.000257 0.000214 0.000161 0.000201
LRT_d 0.1 0.052950 0.050386 0.050286 0.049250 0.000114 0.000102 0.000200 0.000075
0.3 0.050115 0.050408 0.050887 0.050550 0.000118 0.000105 0.000078 0.000099
0.5 0.051150 0.050612 0.051208 0.050205 0.000119 0.000088 0.000198 0.000122
0.7 0.051033 0.051331 0.049037 0.050975 0.000095 0.000080 0.000077 0.000127
mHWP_d 0.1 0.052819 0.049958 0.050091 0.048436 0.000069 0.000092 0.000117 0.000029
0.3 0.050449 0.051010 0.052295 0.051333 0.000013 0.000060 0.000025 0.000030
0.5 0.047014 0.046632 0.046919 0.046702 0.000088 0.000086 0.000134 0.000111
0.7 0.052191 0.051853 0.050738 0.052515 0.000054 0.000060 0.000059 0.000088
eLRT 0.1 0.051798 0.050953 0.053997 0.060978 0.000122 0.000115 0.000093 0.001070
0.3 0.049308 0.051280 0.052182 0.057070 0.000130 0.000166 0.000082 0.000243
0.5 0.051033 0.050921 0.050215 0.052377 0.000125 0.000134 0.000189 0.000223
0.7 0.052914 0.051716 0.049788 0.054130 0.000081 0.000079 0.000095 0.000312
emHWP 0.1 0.051345 0.043123 0.033298 0.018485 0.000030 0.000009 0.000007 ,0.000001
0.3 0.046360 0.039182 0.029185 0.016736 0.000023 0.000018 ,0.000001 ,0.000001
0.5 0.050293 0.050347 0.040255 0.027978 0.000091 0.000057 ,0.000001 0.000041
0.7 0.051471 0.050799 0.049526 0.051332 0.000034 0.000060 0.000051 0.000072
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t007
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We compared the proposed approaches to the existing LRT
approach and mHWP exact test. On the basis of the results of our
simulation studies, when the study of primary disease was
frequency-matched on the secondary phenotype, the existing
LRT and mHWP exact test provided inflated type I error rates for
many scenarios for the different SNPs. In contrast, the newly
proposed emHWP approach uniformly and effectively controlled
the type I error probability in all scenarios examined for different
SNPs associated with the secondary phenotype and/or the
primary disease. For some scenarios (fD is small while fTis large),
the emHWP approach is more likely than the eLRT approach to
keep SNPs associated with the primary disease and/or secondary
phenotype in the analysis. The performance of the emHWP for
less common SNPs (MAF=10%) is similar to that for common
SNPs at different significance levels for all the SNPs. The eLRT
approach, on the other hand, behaved slightly differently at a low
significance level when the SNPs were less common. It tends to
provide inflated type I errors at a low significance level, especially
when the disease is less common but the secondary phenotype is
very common (i.e., fD=0.1 and fT=0.7) and the SNPs are
associated with the primary disease. Therefore, we recommend the
emHWP exact test as a better HWP test that has a greater chance
of keeping potentially associated SNPs for future association
analysis.
In reality, the prevalence values of the primary disease and
secondary phenotype, as well as their joint distribution, cannot be
Table 8. Estimated type I error probability for test of deviation from HWP of SNP3, a causal SNP to secondary phenotype but
unassociated with primary disease (MAF=10%), at 0.05 and 0.0001 significance levels in simulation studies* using different
approaches for HWP testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.050153 0.050133 0.050911 0.052248 0.000080 0.000135 0.000112 0.000056
0.3 0.049309 0.050903 0.049561 0.051465 0.000120 0.000082 0.000117 0.000119
0.5 0.051165 0.049958 0.050187 0.051265 0.000108 0.000064 0.000067 0.000091
0.7 0.050114 0.050480 0.051380 0.050936 0.000130 0.000077 0.000128 0.000052
mHWP_t 0.1 0.050368 0.048035 0.037602 0.024191 0.000043 0.000019 0.000016 0.000013
0.3 0.048566 0.050854 0.042486 0.031576 0.000099 0.000009 ,0.000001 0.000002
0.5 0.049050 0.050853 0.048492 0.041053 0.000122 0.000040 0.000034 0.000007
0.7 0.046458 0.049772 0.051727 0.049122 0.000094 0.000052 0.000084 0.000010
LRT_d 0.1 0.058316 0.073940 0.072316 0.061562 0.000135 0.000253 0.000289 0.000271
0.3 0.054009 0.067947 0.066766 0.060957 0.000112 0.000250 0.000186 0.000199
0.5 0.053243 0.058409 0.061204 0.057918 0.000116 0.000142 0.000220 0.000099
0.7 0.051326 0.053231 0.054928 0.053418 0.000124 0.000075 0.000089 0.000086
mHWP_d 0.1 0.054332 0.068308 0.066194 0.057182 0.000055 0.000132 0.000114 0.000135
0.3 0.051343 0.062151 0.061383 0.056378 0.000032 0.000063 0.000031 0.000086
0.5 0.045976 0.048570 0.050252 0.047917 0.000066 0.000104 0.000110 0.000072
0.7 0.050590 0.051410 0.053220 0.051586 0.000039 0.000015 0.000039 0.000050
eLRT 0.1 0.051076 0.050677 0.054545 0.057184 0.000142 0.000101 0.000154 0.000071
0.3 0.049723 0.050855 0.051065 0.055910 0.000178 0.000066 0.000060 0.000084
0.5 0.051668 0.050298 0.050811 0.054281 0.000129 0.000053 0.000117 0.000073
0.7 0.051233 0.051140 0.051973 0.056249 0.000035 0.000061 0.000173 0.000159
emHWP 0.1 0.049861 0.040333 0.028715 0.015904 0.000039 0.000021 0.000006 ,0.000001
0.3 0.047309 0.038727 0.026424 0.014201 0.000034 0.000002 ,0.000001 ,0.000001
0.5 0.050091 0.048795 0.039083 0.025750 0.000115 0.000026 0.000025 ,0.000001
0.7 0.050428 0.051245 0.051873 0.051315 0.000025 0.000028 0.000076 0.000043
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t008
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the proposed approaches to the estimated prevalence values and
joint distribution using simulations. We considered a range of
primary disease prevalence and conditional probabilities centered
on the true prevalence and true conditional probabilities: [fD – DD,
fD + DD], [fT in cases – D1, fT in cases + D1] and [fT in controls –
D0, fT in controls + D0]. The error terms were defined as 20% of
the true values, for example DD=20% 6 fD. The miss-specified
secondary phenotype prevalence value and joint probabilities can
be evaluated by using the primary disease prevalence and
conditional probabilities defined above. We found that all the
results were very similar to those obtained using the real
prevalence values and joint distribution. Therefore, the misspeci-
fication of prevalence values and joint distribution will not inflate
the type I error rate of the proposed approaches (as in the previous
work [3]). The interactive effects of secondary phenotype and
genetic variants on primary disease might have some impact on
the test for deviation from HWP for genetic variants, which could
be an interesting topic for future study.
In addition to the simulation studies, we also applied the eLRT
and emHWP approaches to a real case-control genetic association
study of lung cancer frequency-matched on smoking status and
compared the numbers of rejected SNPs to those obtained using
the LRT approach in the quality check procedure. In the original
lung cancer study, the lung cancer controls were frequency-
matched by smoking status to the cases. The proposed approaches
always rejected, and thus removed, fewer SNPs than the LRT
approach. We are not claiming that the SNPs kept using our
Table 9. Estimated type I error probability for test of deviation from HWP of SNP4, a SNP unassociated with secondary phenotype
and primary disease (MAF=10%), at 0.05 and 0.0001 significance levels in simulation studies* using different approaches for HWP
testing.
Approaches fD a=0.05 a=0.0001
fT fT
0.1 0.3 0.5 0.7 0.1 0.3 0.5 0.7
LRT_t 0.1 0.049955 0.050560 0.050754 0.051529 0.000103 0.000092 0.000086 0.000119
0.3 0.051255 0.050142 0.050185 0.050944 0.000117 0.000074 0.000141 0.000090
0.5 0.050236 0.050098 0.050188 0.051949 0.000147 0.000081 0.000078 0.000095
0.7 0.050851 0.050228 0.050880 0.051135 0.000037 0.000165 0.000099 0.000092
mHWP_t 0.1 0.048855 0.050711 0.042215 0.028967 0.000066 0.000045 0.000006 ,0.000001
0.3 0.049976 0.050795 0.046092 0.035414 0.000089 0.000044 0.000016 0.000009
0.5 0.047727 0.050971 0.049961 0.043757 0.000117 0.000043 0.000008 ,0.000001
0.7 0.045951 0.049392 0.051668 0.050732 0.000025 0.000169 0.000070 0.000046
LRT_d 0.1 0.051172 0.049296 0.050029 0.050813 0.000096 0.000145 0.000066 0.000052
0.3 0.052033 0.050256 0.050089 0.050230 0.000070 0.000084 0.000031 0.000142
0.5 0.051063 0.049871 0.049610 0.051423 0.000151 0.000073 0.000099 0.000086
0.7 0.051395 0.050905 0.051639 0.050943 0.000083 0.000135 0.000115 0.000121
mHWP_d 0.1 0.050153 0.047861 0.048359 0.049300 0.000076 0.000108 0.000074 0.000052
0.3 0.051980 0.050553 0.050566 0.050233 0.000033 0.000014 0.000026 0.000069
0.5 0.045581 0.044546 0.044106 0.045819 0.000101 0.000062 0.000115 0.000065
0.7 0.051886 0.050960 0.051851 0.051027 0.000031 0.000083 0.000074 0.000079
eLRT 0.1 0.051528 0.051132 0.052837 0.055981 0.000132 0.000197 0.000075 0.000086
0.3 0.052157 0.049806 0.051373 0.053434 0.000089 0.000055 0.000124 0.000068
0.5 0.051175 0.050076 0.049524 0.052920 0.000138 0.000089 0.000126 0.000059
0.7 0.051641 0.051034 0.052126 0.051752 0.000098 0.000104 0.000099 0.000110
emHWP 0.1 0.050713 0.044745 0.032836 0.020672 0.000013 0.000041 ,0.000001 0.000009
0.3 0.050183 0.041807 0.029977 0.017740 0.000007 0.000016 ,0.000001 ,0.000001
0.5 0.049308 0.049678 0.039879 0.029402 0.000125 0.000048 0.000036 ,0.000001
0.7 0.051104 0.050868 0.052230 0.051118 0.000030 0.000077 0.000064 0.000061
*Simulation studies were based on 1,000,000 replicates, each replicate with 2,000 cases in terms of primary disease and 2,000 controls frequency-matched on secondary
phenotype.
MAF: minor allele frequency.
LRT_t: LRT approach, using presence and absence of secondary phenotype as cases and controls.
mHWP_t: mHWP exact test, using presence and absence of secondary phenotype as cases and controls.
LRT_d: LRT approach, using presence and absence of primary disease as cases and controls.
mHWP_d: mHWP exact test, using presence and absence of primary disease as cases and controls.
eLRT: extended LRT approach.
emHWP: extended mHWP exact test.
fD: prevalence of primary disease in general population.
fT: prevalence of secondary phenotype in general population.
doi:10.1371/journal.pone.0027642.t009
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secondary phenotype, as such claims would require validation by
independent studies as dictated by the genome-wide association
study guidelines. Our main goal is to increase the likelihood of not
filtering potentially associated SNPs in the data cleanup stage. In
other words, the eLRT and emHWP approaches have a higher
likelihood of keeping SNPs for further association analysis, and the
additional SNPs kept could potentially be associated with either
the secondary phenotype or primary disease, according to our
simulation results.
To summarize, in this article, we extended the recently
proposed HWP testing approaches, the LRT approach and
mHWP exact test, to frequency-matched case-control study. We
showed that when the study of the primary disease is unmatched,
the proposed eLRT and emHWP approaches are robust and
provide results similar to those obtained with the existing
approaches; when the study of primary disease is frequency-
matched with respect to the secondary phenotype, the proposed
approaches are better HWP tests than the existing approaches. For
frequency-matched studies based on the secondary phenotype, the
eLRT and emHWP approaches will improve our ability to keep
SNPs potentially associated with the secondary phenotype and/or
the primary disease.
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